NEULANDLAB Q4 FY26 Guidance vs Delivery (NEULANDLAB Management Mirror)

Revenue Growth Outlook

Management reaffirmed an aspirational long-term 18-20% CAGR in the Mar'26 Qtr, while emphasizing that growth over the next 2-3 years will remain lumpy with significant quarterly volatility. This maintains consistency with the Dec'25 Qtr, where explicit near-term quantitative guidance was withheld due to order lumpiness, though medium-term growth was viewed as structurally intact. Volume growth from existing products is expected to drive near-term results, with limited new commercializations planned until Mar'27. [Status: Reaffirmed]